Co-medication with disulfiram markedly increased serum clozapine levels: Two case reports
- PMID: 36703576
- PMCID: PMC9912305
- DOI: 10.1177/02698811221148611
Co-medication with disulfiram markedly increased serum clozapine levels: Two case reports
Abstract
Background: Alcohol use disorder (AUD) is a significant co-morbidity in patients with schizophrenia. Clozapine offers some benefits in treating patients with refractory schizophrenia and AUD, but co-medicating with disulfiram is also common.
Procedures: We report two cases where co-medicating with disulfiram led to a significant increase in clozapine serum levels.
Findings: Clozapine serum levels decreased to one-third in Patient 1 when disulfiram was discontinued and started to increase again when disulfiram was reintroduced. Patient 2 developed toxic serum levels of clozapine during disulfiram treatment combined with heavy coffee drinking and symptoms reminiscent of neuroleptic malignant syndrome.
Conclusions: Clozapine and disulfiram are both metabolized by cytochrome P450 CYP1A2 and clinically relevant interaction through this shared pathway is possible.
Keywords: Alcohol use disorder; clozapine; disulfiram; interaction; toxicity.
Conflict of interest statement
The author(s) declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.
Similar articles
-
Short-term use of disulfiram with clozapine.J Clin Psychopharmacol. 1994 Jun;14(3):213-5. J Clin Psychopharmacol. 1994. PMID: 8027424 No abstract available.
-
Time to rehospitalization of clozapine versus risperidone in the naturalistic treatment of comorbid alcohol use disorder and schizophrenia.Prog Neuropsychopharmacol Biol Psychiatry. 2008 May 15;32(4):984-8. doi: 10.1016/j.pnpbp.2008.01.009. Epub 2008 Jan 18. Prog Neuropsychopharmacol Biol Psychiatry. 2008. PMID: 18262321
-
Use of lamotrigine to augment clozapine in patients with resistant schizophrenia and comorbid alcohol dependence: a potent anti-craving effect?J Psychopharmacol. 2005 May;19(3):301-5. doi: 10.1177/0269881105051542. J Psychopharmacol. 2005. PMID: 15888516
-
Treatment of schizophrenia and comorbid substance abuse: pharmacologic approaches.J Clin Psychiatry. 2006;67 Suppl 7:31-5; quiz 36-7. J Clin Psychiatry. 2006. PMID: 16961422 Review.
-
Pharmacogenetics of antipsychotic treatment: lessons learned from clozapine.Biol Psychiatry. 2000 Feb 1;47(3):252-66. doi: 10.1016/s0006-3223(99)00298-x. Biol Psychiatry. 2000. PMID: 10682223 Review.
Cited by
-
Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part I: A Review of the Pharmacokinetic Literature and Proposed Changes.J Clin Psychopharmacol. 2025 May-Jun 01;45(3):179-196. doi: 10.1097/JCP.0000000000001987. Epub 2025 Apr 9. J Clin Psychopharmacol. 2025. PMID: 40198781 Free PMC article. Review.
-
Evaluation of major adverse events of clozapine based on accordance to an international titration guideline.Ment Health Clin. 2024 Jun 3;14(3):204-211. doi: 10.9740/mhc.2024.06.204. eCollection 2024 Jun. Ment Health Clin. 2024. PMID: 38835819 Free PMC article.
References
-
- Abomics (n.d.) Pharmacogenetics applied into clinical practice. Available at: https://www.abomics.fi/en/ (accessed 9 May 2022).
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical